Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
公司代碼FLGT
公司名稱Fulgent Genetics Inc
上市日期Sep 28, 2016
CEOHsieh (Ming)
員工數量1313
證券類型Ordinary Share
年結日Sep 28
公司地址4399 Santa Anita Ave
城市EL MONTE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編91731
電話16263500537
網址https://www.fulgentgenetics.com/
公司代碼FLGT
上市日期Sep 28, 2016
CEOHsieh (Ming)